Citadel Advisors
VERA icon

Citadel Advisors’s Vera Therapeutics VERA Stock Holding History

Citadel Advisors’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$700K Buy
17,400
+1,600
+10% +$68.9K ﹤0.01% 8495
2025
Q4 		$800K Buy
15,800
+1,400
+10% +$49.7K ﹤0.01% 7921
2025
Q3 		$418K Sell
14,400
-63,300
-81% -$1.46M ﹤0.01% 9560
2025
Q2 		$1.83M Buy
77,700
+68,700
+763% +$1.54M ﹤0.01% 5867
2025
Q1 		$216K Sell
9,000
-20,700
-70% -$665K ﹤0.01% 10303
2024
Q4 		$1.26M Buy
29,700
+1,800
+6% +$79.7K ﹤0.01% 6559
2024
Q3 		$1.23M Sell
27,900
-4,400
-14% -$167K ﹤0.01% 6432
2024
Q2 		$1.17M Sell
32,300
-25,400
-44% -$1.01M ﹤0.01% 6284
2024
Q1 		$2.49M Buy
57,700
+55,700
+2,785% +$1.98M ﹤0.01% 5095
2023
Q4 		$30.8K Buy
+2,000
New +$25.4K ﹤0.01% 12246
2023
Q3 		– Sell
-10,400
Closed -$167K – 15180
2023
Q2 		$167K Buy
10,400
+8,600
+478% +$77.7K ﹤0.01% 10166
2023
Q1 		$14K Buy
+1,800
New +$13.9K ﹤0.01% 13330

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors's VERA Position: Q1 2026 in Review

Citadel Advisors reduced its Vera Therapeutics (VERA) stake by 45% in Q1 2026, selling an estimated $15M and leaving 429,761 shares worth $17.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2503.

Citadel Advisors first reported a position in VERA in Q2 2021 and has held it in 19 quarters since. The position peaked at $49.1M in Q1 2022. 229 funds tracked by Wall St. Rank hold VERA as of Q1 2026.

  • Citadel Advisors held 429,761 shares of Vera Therapeutics worth $17.3M as of Q1 2026.
  • Citadel Advisors sold 347,727 Vera Therapeutics shares in Q1 2026, an estimated $15M.
  • Vera Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2503 holding.
  • Citadel Advisors first reported a position in Vera Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Citadel Advisors's Vera Therapeutics position peaked at $49.1M in Q1 2022.
  • 229 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.